Table 1.
NH White | NH Black | Hispanic | Asian/PI | Chi‐square P value | |||||
---|---|---|---|---|---|---|---|---|---|
N | % | N | % | N | % | N | % | ||
Age | |||||||||
<50 | 431 | 6.3 | 56 | 5.4 | 261 | 15.6 | 150 | 13.5 | <0.0001 |
50‐59 | 1355 | 19.9 | 196 | 18.8 | 417 | 24.9 | 343 | 30.9 | |
60‐69 | 1850 | 27.1 | 412 | 39.5 | 517 | 30.9 | 314 | 28.3 | |
70‐79 | 1836 | 26.9 | 268 | 25.7 | 331 | 19.8 | 206 | 18.5 | |
80+ | 1348 | 19.8 | 111 | 10.6 | 147 | 8.8 | 98 | 8.8 | |
Histologic subtype | |||||||||
Serous | 1113 | 16.3 | 254 | 24.4 | 316 | 18.9 | 188 | 16.9 | <0.0001 |
High‐grade endometrioid | 3141 | 46.1 | 331 | 31.7 | 699 | 41.8 | 508 | 45.7 | |
Clear cell | 344 | 5.0 | 61 | 5.8 | 90 | 5.4 | 63 | 5.7 | |
Carcinosarcoma/Mullerian mixed | 1094 | 16.0 | 260 | 24.9 | 304 | 18.2 | 173 | 15.6 | |
Mixed | 1128 | 16.5 | 137 | 13.1 | 264 | 15.8 | 179 | 16.1 | |
FIGO stage equivalent | |||||||||
I | 3126 | 45.8 | 411 | 39.4 | 705 | 42.1 | 484 | 43.6 | <0.0001 |
II | 614 | 9.0 | 111 | 10.6 | 162 | 9.7 | 99 | 8.9 | |
III | 1574 | 23.1 | 244 | 23.4 | 394 | 23.6 | 290 | 26.1 | |
IV | 1241 | 18.2 | 217 | 20.8 | 347 | 20.7 | 215 | 19.4 | |
Unknown | 265 | 3.9 | 60 | 5.8 | 65 | 3.9 | 23 | 2.1 | |
Number LN examined | |||||||||
None | 2061 | 30.2 | 423 | 40.6 | 585 | 35.0 | 282 | 25.4 | <0.0001 |
1‐9 | 1432 | 21.0 | 223 | 21.4 | 314 | 18.8 | 244 | 22.0 | |
10 or more | 3059 | 44.9 | 368 | 35.3 | 731 | 43.7 | 555 | 50.0 | |
Unknown | 268 | 3.9 | 29 | 2.8 | 43 | 2.6 | 30 | 2.7 | |
Number LN positivea | |||||||||
None | 3528 | 74.1 | 424 | 68.4 | 785 | 72.2 | 592 | 71.4 | 0.0820 |
1 | 379 | 8.0 | 62 | 10.0 | 105 | 9.7 | 85 | 10.3 | |
2‐5 | 528 | 11.1 | 77 | 12.4 | 122 | 11.2 | 90 | 10.9 | |
>5 | 255 | 5.4 | 49 | 7.9 | 64 | 5.9 | 52 | 6.3 | |
Unknown | 69 | 1.4 | 8 | 1.3 | 12 | 1.1 | 10 | 1.2 | |
Radiation | |||||||||
None | 4379 | 64.2 | 711 | 68.2 | 1037 | 62.0 | 679 | 61.1 | 0.0241 |
External Beam | 1509 | 22.1 | 206 | 19.8 | 406 | 24.3 | 295 | 26.6 | |
Brachytherapy | 330 | 4.8 | 44 | 4.2 | 77 | 4.6 | 39 | 3.5 | |
Beam + Brachytherapy | 542 | 7.9 | 72 | 6.9 | 142 | 8.5 | 91 | 8.2 | |
Radiation, NOS | 59 | 0.9 | 10 | 1.0 | 11 | 0.7 | 7 | 0.6 | |
Unknown | <5 | 0.0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Chemotherapy | |||||||||
No | 5041 | 73.9 | 759 | 72.8 | 1128 | 67.4 | 756 | 68.0 | <0.0001 |
Yes | 1779 | 26.1 | 284 | 27.2 | 545 | 32.6 | 355 | 32.0 | |
Charlson Comorbidity Index | |||||||||
Unknown | 318 | 4.7 | 64 | 6.1 | 172 | 10.3 | 87 | 7.8 | <0.0001 |
0 | 4500 | 66.0 | 535 | 51.3 | 936 | 55.9 | 697 | 62.7 | |
1 | 1379 | 20.2 | 255 | 24.4 | 388 | 23.2 | 250 | 22.5 | |
2+ | 623 | 9.1 | 189 | 18.1 | 177 | 10.6 | 77 | 6.9 | |
Neighborhood SES quintile | |||||||||
1‐ Lowest SES | 573 | 8.4 | 315 | 30.2 | 515 | 30.8 | 108 | 9.7 | <0.0001 |
2 | 1104 | 16.2 | 279 | 26.7 | 438 | 26.2 | 192 | 17.3 | |
3 ‐ Middle SES | 1521 | 22.3 | 212 | 20.3 | 326 | 19.5 | 232 | 20.9 | |
4 | 1660 | 24.3 | 148 | 14.2 | 240 | 14.3 | 284 | 25.6 | |
5 ‐ Highest SES | 1962 | 28.8 | 89 | 8.5 | 154 | 9.2 | 295 | 26.6 | |
Primary payer | |||||||||
None | 87 | 1.3 | 25 | 2.4 | 97 | 5.8 | 36 | 3.2 | <0.0001 |
Private | 3548 | 52.0 | 520 | 49.9 | 778 | 46.5 | 605 | 54.5 | |
Public/Medicaid, VA | 489 | 7.2 | 178 | 17.1 | 396 | 23.7 | 221 | 19.9 | |
Medicare | 2469 | 36.2 | 302 | 29.0 | 333 | 19.9 | 205 | 18.5 | |
Unknown | 227 | 3.3 | 18 | 1.7 | 69 | 4.1 | 44 | 4.0 | |
Seen at NCI‐designated cancer center | |||||||||
No | 6069 | 89.0 | 913 | 87.5 | 1367 | 81.7 | 913 | 82.2 | <0.0001 |
Yes | 751 | 11.0 | 130 | 12.5 | 306 | 18.3 | 198 | 17.8 | |
Total | 6820 | 100.0 | 1043 | 100.0 | 1673 | 100.0 | 1111 | 100.0 |
Among women with lymph nodes removed.